Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul 31;12(7):1628-1630.
doi: 10.21037/tlcr-23-215. Epub 2023 Jun 5.

Tarlatamab: a potential new option for recurrent small cell lung cancer

Alfredo Addeo  1 , Giuseppe Luigi Banna  2 , Alex Friedlaender  1   3
Affiliations
Editorial

Tarlatamab: a potential new option for recurrent small cell lung cancer

Alfredo Addeo et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Small cell lung cancer (SCLC); bispecific T-cell engager (BiTE); tarlatamab.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-215/coif). AA reports personal fees from Roche, Pfizer, Astellas, AstraZeneca, MSD, Sanofi, Novartis, Janssen, BMS, Takeda, Bayer, Amgen. GLB reports personal fees from AstraZeneca, Astellas, travel and conference expenses from Janssen, outside the submitted work. AF reports personal fees from Roche, Pfizer, Astellas, AstraZeneca, MSD, Sanofi, Novartis, Janssen, BMS, Takeda, Bayer.

Comment on

References

    1. Available online: https://www.nccn.org/patients/guidelines/content/PDF/SCLC-patient-guidel....
    1. Lammers PE, Shyr Y, Li CI, et al. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. J Thorac Oncol 2014;9:559-62. 10.1097/JTO.0000000000000079 - DOI - PMC - PubMed
    1. Available online: https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/....
    1. Singh S, Jaigirdar AA, Mulkey F, et al. FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer. Clin Cancer Res 2021;27:2378-82. 10.1158/1078-0432.CCR-20-3901 - DOI - PMC - PubMed
    1. Baize N, Monnet I, Greillier L, et al. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2020;21:1224-33. 10.1016/S1470-2045(20)30461-7 - DOI - PubMed